You have read all your free articles, to continue reading subscribe to read the rest of this content.
Lundbeck has announced results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study that assessed the efficacy and tolerability of Vyepti when initiated during a migraine attack in patients who are candidates for preventive therapy. The study met statistical significAlready a subscriber Login You have read all your free articles,…
BerGenBio has provided an update from the company’s phase II study of bemcentinib (BGB324), an oral AXL inhibitor, in combination with low-dose cytarabine (LDAC) in elderly AML patients. The bemcentinib-LDAC combination was safe and well tolerated in elderly AML patients and showed promising efAlready a subscriber Login You have read…
RhoVac has received and validated results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 2018. The top-line results shows that the vast majority of patients still had undetectable PSA. Furthermore, the RhoC specific immune response has so farAlready a…
Calliditas Therapeutics has announced that the first patient in China has been randomized into confirmatory part of the NefIgArd Phase 3 trial by its partner, Everest Medicines. Following IND approval by the NMPA in December of 2019 and subsequent approval by Human Genetic Resources AdministratioAlready a subscriber Login You have…
